BioCentury | Feb 8, 2019
Emerging Company Profile

Palleon: Sweeter checkpoints

...NYSE:PFE), New York, N.Y. The Rockefeller University, New York, N.Y. Elizabeth S. Eaton, Staff Writer Palleon Pharmaceuticals Inc. Sialic acid binding Ig like lectin (SIGLEC) glycans glyco-immune...
BioCentury | Jan 13, 2017
Financial News

OncoImmune raises $15M in series A

OncoImmune Inc. (Rockville, Md.) said it raised $15 million in a series A round led by 3E Bioventures Capital. The company's lead candidate, CD24Fc , is in a Phase II study to prevent graft versus host...
BioCentury | Oct 8, 2015
Distillery Therapeutics

Therapeutics: Sialic acid binding Ig-like lectin (SIGLEC)

Infectious disease INDICATION: Sepsis Cell culture and mouse studies identified a SIGLEC inhibitor that could help treat sepsis. In mouse macrophage culture, a compound composed of an analog of the natural SIGLEC ligand, N-acetylneuraminic acid,...
BioCentury | Jul 14, 2014
Company News

Scripps Research Institute, T23 deal

T23 received exclusive, worldwide rights to develop and commercialize Scripps’ CD22 sialic acid binding Ig-like lectin (SIGLEC) oncoimmunological platform. The license covers complex formulations combining cytotoxins, SIGLEC-targeting ligands and liposomal or other delivery systems. T23...
BioCentury | Jun 27, 2013
Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Sialic acid binding Ig-like lectin (SIGLEC)-engaging, tolerance-inducing antigenic liposomes (STALs) to suppress antibody response Mouse studies identified STALs that could help...
Items per page:
1 - 5 of 5